SCHEMBL5963897

SCHEMBL5963897

N#CCc1ccc(C(=O)O)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
EPHX2 P34913 2/20 0.47
NR1H4 Q96RI1 1/20 0.47
NR4A2 P43354 3/20 0.44
NR4A1 P22736 1/20 0.44
NR4A3 Q92570 1/20 0.44
SRD5A2 P31213 1/20 0.43
ALOX15 P16050 2/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
TTR P02766 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MRGPRX4 Q96LA9 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
RORC P51449 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832729 0.86 TSHR (0.36) TSHREPHX2NR1H4NR4A2NR4A1
SCHEMBL1246794 0.86 TSHR (0.53) TSHREPHX2NR4A2NR4A1NR4A3
SCHEMBL11811926 0.81 EPHX2 (0.40) TSHREPHX2NR1H4NR4A2NR4A1
SCHEMBL19330876 0.81 ALDH1A1 (0.47) TSHRALOX15HTTALDH1A1MAPT
SCHEMBL31161847 0.81 ALDH1A1 (0.47) TSHRALOX15HTTALDH1A1MAPT
SCHEMBL17198001 0.78 TSHR (0.61) TSHREPHX2NR1H4NR4A2NR4A1
SCHEMBL6659614 0.78 TSHR (0.61) TSHREPHX2NR1H4NR4A2NR4A1
SCHEMBL5963476 0.77 GABRA1 (0.41) EPHX2NR1H4ALOX15SMN1; SMN2
SCHEMBL4837416 0.77 TSHR (0.59) TSHREPHX2NR1H4NR4A2NR4A1
SCHEMBL2259867 0.77 TSHR (0.59) TSHREPHX2NR1H4NR4A2NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3884939-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-10-25 EP disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 US disclosed
EP-3884939-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2021-09-29 EP disclosed
EP-3426243-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2021-05-19 EP disclosed
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-03-23 US disclosed
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 US disclosed
US-7119073-B2 Peptides and their use as inhibitors of hepatitis C virus ns3 protease ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2006-10-10 US disclosed
US-20040142876-A1 Peptides and their use as inhibitors of hepatitis c virus ns3 protease ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2004-07-22 US disclosed
EP-1392721-A1 PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2004-03-03 EP disclosed
WO-2002079234-A1 PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142876-A1 Peptides and their use as inhibitors of hepatitis c virus ns3 protease CTRL, VIP, CTSC TSHR 3552/4885EPHX2 2932/4885NR1H4 449/4885
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD TSHR 4686/4885EPHX2 1625/4885NR1H4 4182/4885
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD TSHR 4686/4885EPHX2 1625/4885NR1H4 4182/4885
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD TSHR 4686/4885EPHX2 1625/4885NR1H4 4182/4885
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD TSHR 4686/4885EPHX2 1625/4885NR1H4 4182/4885
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD TSHR 4686/4885EPHX2 1625/4885NR1H4 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.